Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 2/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | BRAF | P15056 | 2/20 | 0.35 |
| ▸ | PI4KA | P42356 | 2/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9154126 | 0.90 | GDA (0.35) | GDAPDPK1CDK2DPP4ALDH1A1 | |
| SCHEMBL1275417 | 0.83 | PDPK1 (0.44) | GDAPDPK1CDK2DPP4ALDH1A1 | |
| Xanthine SCHEMBL4966 | 0.79 | GDA (0.44) | GDAPDPK1CDK2DPP4ALDH1A1 | |
| Xanthine SCHEMBL9443819 | 0.79 | GDA (0.44) | GDAPDPK1CDK2DPP4ALDH1A1 | |
| Xanthine SCHEMBL7044234 | 0.78 | GDA (0.42) | GDAPDPK1CDK2DPP4ALDH1A1 | |
| SCHEMBL16146331 | 0.76 | DPP4 (0.61) | GDAPDPK1CDK2DPP4ALDH1A1 | |
| SCHEMBL9465644 | 0.76 | GDA (0.41) | GDAPDPK1CDK2DPP4ALDH1A1 | |
| Isoguanine SCHEMBL29569323 | 0.76 | PDPK1 (0.66) | GDAPDPK1CDK2DPP4PNP | |
| SCHEMBL1724116 | 0.76 | GDA (0.41) | GDAPDPK1CDK2DPP4ALDH1A1 | |
| Isoguanine SCHEMBL887741 | 0.76 | PDPK1 (0.66) | GDAPDPK1CDK2DPP4PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114699419-A | Use of a PLpro protein inhibitor in a medicament for the treatment or prevention of a novel coronavirus infection | 北京大学深圳研究生院 | 2022-07-05 | — | — | CN | claimed |
| CN-112022855-A | Use of a PLpro protein inhibitor in a medicament for the treatment or prevention of a novel coronavirus infection | 北京大学深圳研究生院 | 2020-12-04 | — | — | CN | claimed |
| CN-104447746-A | Compound for activating AMPK and application thereof | HUAAN MEDICAL CO LTD | 2015-03-25 | — | — | CN | claimed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| US-6369208-B1 | INFLUENZA ENDONUCLEASE APATAMER THAT INHIBITS INFLUENZA ENDONUCLEASE AND IS RESISTANT TO CLEAVAGE BY SAID ENZYME | MERCK & CO., INC. | 2002-04-09 | — | — | US | claimed |
| JP-3257675-B2 | — | — | 2002-02-18 | — | — | JP | claimed |
| US-5817635-A | RNA MOLECULES WITH CATALYTIC ACTIVITY | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1998-10-06 | — | — | US | claimed |
| EP-0552178-B1 | MODIFIED RIBOZYMES | MAX PLANCK GESELLSCHAFT (DE) | 1997-01-02 | — | — | EP | claimed |
| EP-0552178-A1 | MODIFIED RIBOZYMES. | MAX PLANCK GESELLSCHAFT (DE) | 1993-07-28 | — | — | EP | claimed |
| WO-1992007065-A1 | MODIFIED RIBOZYMES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1992-04-30 | — | — | WO | claimed |
| US-20260056202-A1 | USE OF MODIFIED PHAGE FOR CAPTURING AND SUBTYPING OF CANCER CELLS | UNIV HONG KONG CHINESE (CN) | 2026-02-26 | — | — | US | disclosed |
| US-12553054-B2 | Compositions and methods related to nucleic acid anticoagulants | NORTH CAROLINA STATE UNIVERSITY (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260009038-A1 | COMPOSITIONS AND METHODS RELATED TO NUCLEIC ACID SENSORS | UNIV ARIZONA STATE (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4605550-A2 | COMPOSITIONS AND METHODS RELATED TO NUCLEIC ACID SENSORS | Arizona Board of Regents on behalf of Arizona State University (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250188517-A1 | COMPOSITIONS AND METHODS RELATED TO NUCLEIC ACID SENSORS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2025-06-12 | — | — | US | disclosed |
| WO-1992007065-A1 | MODIFIED RIBOZYMES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1992-04-30 | — | — | WO | disclosed |
| US-5021574-A | Cardiotonic agents, antiarrhythmia agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-06-04 | — | — | US | disclosed |
| US-4294920-A | PEPTIZATION, PROTECTIVE COLLOIDS | AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) | 1981-10-13 | — | — | US | disclosed |
| EP-0005200-B1 | SILVER HALIDE PHOTOGRAPHIC MATERIAL AND METHOD OF PREPARATION | Agfa-Gevaert AG (DE) | 1981-04-15 | — | — | EP | disclosed |
| EP-0005200-A2 | Silver halide photographic material and method of preparation | Agfa-Gevaert AG (DE) | 1979-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | GDA 1170/4885PDPK1 281/4885CDK2 1757/4885 |
| US-20260009038-A1 | COMPOSITIONS AND METHODS RELATED TO NUCLEIC ACID SENSORS | ADAR, ADA, YARS1 | GDA 4/4885PDPK1 3536/4885CDK2 3742/4885 |
| US-12553054-B2 | Compositions and methods related to nucleic acid anticoagulants | NSUN2, NSUN3, ADAR | GDA 2549/4885PDPK1 3573/4885CDK2 2524/4885 |
| US-20260056202-A1 | USE OF MODIFIED PHAGE FOR CAPTURING AND SUBTYPING OF CANCER CELLS | DNMT3A, SELPLG, TP53 | GDA 1621/4885PDPK1 3898/4885CDK2 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.